Clinical trials: Corneal Neovascularization
Corneal Neovascularization
Treatment of Corneal Neovascularization With Topical Pazopanib
The purpose of this study is to determine the safety and efficacy of a drug [Pazopanib (Votrient)] as a treatment for corneal neovascularization.
- Trial name
- NCT01257750
- Testing
- Pazopanib (5mg/ml)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Reza Dana, MD
Corneal Neovascularization
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.
- Trial name
- NCT00512876
- Testing
- Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Walter Reed Army Medical Center
Corneal Neovascularization
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.
- Trial name
- NCT00681889
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Reza Dana, MD
Limbal Stem Cell Deficiency
Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft
The main aim of the study is to determine the safety and feasibility of a cultivated autologous limbal epithelial cell (CALEC) transplantation in the treatment of limbal stem cell deficiency.
- Trial name
- CALEC (NCT02592330)
- Testing
- Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Corneal Neovascularization
Topical IL-1-Ra for Treatment of Corneal Neovascularization
The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.
- Trial name
- NCT00915590
- Testing
- IL-1Ra
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Reza Dana, MD
Corneal Neovascularization
Topical Avastin for Treatment of Corneal Neovascularization
The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.
- Trial name
- NCT00559936
- Testing
- Topical Avastin 1%
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Corneal Neovascularization, Corneal Graft Failure
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
The leading risk factor for corneal transplant rejection is abnormal blood vessel growth of the host bed. Vascular endothelial growth factor (VEGF) is thought to be a mediator of this corneal neovascularization (NV), therefore we…
- Trial name
- NCT01072357
- Testing
- Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Reza Dana, MD
Corneal Neovascularization, Corneal Graft Failure
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe and effective at decreasing the likelihood of a high-risk corneal graft rejection.
- Trial name
- NCT01996826
- Testing
- Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Reza Dana, MD